IL6 and prostate cancer: Some studies have reported that the addition of exogenous IL-6 to the culture media of prostate cancer LNCaP cells resulted in a dose-dependent growth inhibition with neuroendocrine differentiation [43, 44], whereas in other instances, cell proliferation was increased [42–48].